title: Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells.
abstract: A major goal of immunotherapy for autoimmune diseases and transplantation is induction of regulatory T cells that mediate immunologic tolerance. The mucosal immune system is unique, as tolerance is preferentially induced after exposure to antigen, and induction of regulatory T cells is a primary mechanism of oral tolerance. Parenteral administration of CD3-specific monoclonal antibody is an approved therapy for transplantation in humans and is effective in autoimmune diabetes. We found that orally administered CD3-specific antibody is biologically active in the gut and suppresses autoimmune encephalomyelitis both before induction of disease and at the height of disease. Orally administered CD3-specific antibody induces CD4+ CD25- LAP+ regulatory T cells that contain latency-associated peptide (LAP) on their surface and that function in vitro and in vivo through a TGF-beta-dependent mechanism. These findings identify a new immunologic approach that is widely applicable for the treatment of human autoimmune conditions.
authors.affiliation: Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA.
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Ochi
authors.forename: Michal
authors.initials: M
authors.lastname: Abraham
authors.forename: Hiroki
authors.initials: H
authors.lastname: Ishikawa
authors.forename: Dan
authors.initials: D
authors.lastname: Frenkel
authors.forename: Kaiyong
authors.initials: K
authors.lastname: Yang
authors.forename: Alexandre S
authors.initials: AS
authors.lastname: Basso
authors.forename: Henry
authors.initials: H
authors.lastname: Wu
authors.forename: Mei-Ling
authors.initials: ML
authors.lastname: Chen
authors.forename: Roopali
authors.initials: R
authors.lastname: Gandhi
authors.forename: Ariel
authors.initials: A
authors.lastname: Miller
authors.forename: Ruth
authors.initials: R
authors.lastname: Maron
authors.forename: Howard L
authors.initials: HL
authors.lastname: Weiner
mesh_terms: D000284:Administration, Oral; D019264:Adoptive Transfer; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use; D017252:CD3 Complex / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology*; D006224:Cricetinae; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D010455:Peptides / Q000235:genetics / Q000276:immunology*; D015375:Receptors, Interleukin-2 / Q000235:genetics / Q000276:immunology*; D016176:T-Lymphocyte Subsets / Q000166:cytology / Q000276:immunology*; D016212:Transforming Growth Factor beta / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D017252:CD3 Complex; D010455:Peptides; D015375:Receptors, Interleukin-2; D016212:Transforming Growth Factor beta